Cybin Inc. to Participate in Cantor Global Healthcare Conference, Highlighting Neuropsychiatry Advancements

Cybin Inc., a clinical-stage neuropsychiatry company, announced that Chief Medical Officer Amir Inamdar will participate in a fireside chat at the Cantor Global Healthcare Conference scheduled for September 3-5, 2025. The session will be webcast live on Friday, September 5, at 10:20 a.m. ET, with an archived replay available on Cybin's investor relations website. This participation matters as it provides a platform to discuss the company's innovative mental health treatments, particularly CYB003 and CYB004, which are advancing through clinical trials with promising data.

The conference appearance is significant because Cybin is developing next-generation treatment options that address large unmet needs in mental healthcare. The company's lead candidate, CYB003, is a proprietary deuterated psilocin analog in Phase 3 studies for adjunctive treatment of major depressive disorder. It has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential to offer substantial improvement over existing therapies. This designation accelerates the development and review process, which could lead to faster patient access to effective treatments.

Additionally, Cybin is developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The implications of these developments are profound, as mental health conditions affect millions worldwide, and current treatments often have limitations in efficacy and durability. Cybin's research pipeline focuses on 5-HT-receptor compounds, aiming to provide novel drugs that deliver effective and lasting results. The company's work could revolutionize the mental health treatment landscape, offering new hope for patients who do not respond adequately to existing options.

The Cantor Global Healthcare Conference serves as a critical venue for Cybin to engage with investors, healthcare professionals, and stakeholders, emphasizing the importance of innovation in neuropsychiatry. By sharing updates on clinical progress and strategic direction, Cybin can bolster confidence in its approach and highlight the broader implications for mental healthcare advancement. For more details, visit https://ibn.fm/N8ObB. This participation not only raises awareness but also underscores the growing recognition of psychedelic-derived therapies as viable options in mainstream medicine, potentially reshaping treatment paradigms and reducing the stigma associated with mental health disorders.